4-EA-NBOMe

From WikiMD's WELLNESSPEDIA


Chemical structure of 4-EA-NBOMe

4-EA-NBOMe is a synthetic psychedelic compound belonging to the NBOMe class. It is a derivative of the phenethylamine 4-ethylanisole and is known for its potent hallucinogenic effects. The compound is structurally related to other NBOMe substances, which are known for their high affinity for the 5-HT2A receptor.

Chemical Properties[edit]

4-EA-NBOMe is characterized by the presence of a methoxybenzyl group attached to the nitrogen atom of the phenethylamine backbone. This modification is responsible for its increased potency compared to its parent compound, 4-ethylanisole. The chemical structure of 4-EA-NBOMe can be represented by the formula C18H23NO3.

Pharmacology[edit]

4-EA-NBOMe acts primarily as a partial agonist at the 5-HT2A receptor, which is the primary target for classical psychedelics such as LSD and psilocybin. The activation of this receptor is believed to be responsible for the psychedelic effects experienced by users. The compound may also interact with other serotonin receptors, contributing to its overall pharmacological profile.

Effects[edit]

The effects of 4-EA-NBOMe are similar to those of other NBOMe compounds and include visual hallucinations, altered perception of time, and changes in mood and thought processes. The onset of effects typically occurs within 30 to 90 minutes after administration, with the peak effects lasting for several hours. Users may experience both positive and negative effects, including euphoria, introspection, anxiety, and confusion.

Safety and Toxicity[edit]

The safety profile of 4-EA-NBOMe is not well-established, and there is limited information on its toxicity in humans. As with other NBOMe compounds, there is a risk of overdose, which can lead to severe adverse effects such as vasoconstriction, hypertension, tachycardia, and seizures. Due to these risks, the use of 4-EA-NBOMe is discouraged outside of controlled research settings.

Legal Status[edit]

The legal status of 4-EA-NBOMe varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other banned NBOMe compounds. Users should be aware of the legal implications of possessing or distributing this substance in their region.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=4-EA-NBOMe&oldid=6622532"